Market Overview
The market is primarily driven by an increasing patient pool owing to the increasing female geriatric population and growing prevalence of hormonal disorders, and changing lifestyles. For instance, uterine fibroids affect nearly 40% of women in 30 to 55. Moreover, the advent of minimally invasive and effective alternatives to open surgeries favors the market. North America dominates the market for Uterine Fibroids Treatment. Asia Pacific is expected to witness the fastest market growth due to its high prevalence of gynecological problems and awareness about uterine fibroid treatment in the region, coupled with rapidly rising healthcare R&D investment.
Market Dynamics
Drivers
- Rising incidences of uterine fibroids
- Increasing technological advancements
- Growing awareness towards uterine fibroids
Restraints
- Complications associated with surgical treatments
- Low awareness towards treatment options
Market Segmentation
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used first-line drugs to treat different medical situations in the field of obstetrics and gynecology. Their anti-inflammatory properties make them most useful in managing disorders in which pain is related to the intensity of the inflammatory process.
Non-hormonal options include tranexamic acid (Lysteda), which can lighten bleeding and is taken on the days when the period is heavy. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen can help relieve fibroid pain. Naproxen (Naprosyn, Aleve, Naprelan) is for relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing cyclooxygenase activity, which is responsible for prostaglandin synthesis. NSAIDs decrease intraglomerular pressure and decrease proteinuria.
The currently available traditional NSAIDs act by inhibiting the prostaglandin G/H synthase enzymes, known as the cyclooxygenases. Those enzymes convert arachidonic acid to the unstable intermediates prostaglandin G2 and prostaglandin H2 and lead to the production of thromboxane A2 and various other prostaglandins, which contribute to pain. In obstetrics and gynecology, NSAIDs have long been used to control acute and chronic postoperative pain, menstrual pain, pain related to medical abortions, menorrhagia, intrauterine device, assist infertility treatment, and administered as tocolytics in preterm labor.
Geographical Analysis
North America is growing at the fastest CAGR of 4.91% during the forecast period (2019-2026).
North America holds 31.18% of the market share in 2018 and is expected to be 32.48% by 2026 for the Uterine Fibroids Treatment Market. The Uterine Fibroids Treatment market's collective revenue in North America is expected to generate USD 3,533.7 Mn from 2019-2026.
North America has been the largest market for uterine fibroid treatment, owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing uterine cancer prevalence is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by 50 years among women. Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and frequent product innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the uterine fibroids treatment growth market.
Competitive Analysis
In the uterine fibroids market, companies focus on developing new women's healthcare products and strategic moves to acquire greater market share. Efficient distribution networks, product differentiation, and supply competency play a major role in determining such players' market position. The majority of these players focus on expanding distribution networks and expanding presence in the Asia Pacific, Latin America, and the Middle East regions due to increasing awareness about uterine fibroids among the female population.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com